Your browser doesn't support javascript.
loading
Cost-effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China.
Xu, Zhe; Ye, Zhuo-Miao; Tang, Yu-Kai; Deng, Dong-Feng; Zhou, Qin; Fang, Man; Zhang, Ying-Ying; Li, Xiang-Ping.
Afiliação
  • Xu Z; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Ye ZM; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Tang YK; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Deng DF; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Zhou Q; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Fang M; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Zhang YY; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Li XP; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Cancer Med ; 12(14): 14871-14880, 2023 07.
Article em En | MEDLINE | ID: mdl-37434398
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Health_economic_evaluation Limite: Aged / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Health_economic_evaluation Limite: Aged / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article